Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, HBeAg+, Chronic Hepatitis B Patients

Trial Profile

Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, HBeAg+, Chronic Hepatitis B Patients

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs INO 1800 (Primary) ; INO 9112 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Inovio Pharmaceuticals; Roche
  • Most Recent Events

    • 08 Aug 2017 According to an Inovio Pharmaceuticals media release, the company expects to report data from this study in the fourth quarter of 2017.
    • 15 Mar 2017 Status changed from recruiting to active, no longer recruiting, as reported in an Inovio media release.
    • 08 Sep 2016 Planned number of patients changed from 126 to 90.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top